GAITHERSBURG, Md. & WEESP, Netherlands--(BUSINESS WIRE)--Gene Logic Inc. (NASDAQ: GLGC) announced today that it has entered into a drug repositioning and development agreement with Solvay Pharmaceuticals, a division of the Solvay Group (Euronext : SOLB.BE), to seek alternative development paths for multiple Solvay drug candidates. All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.
